BioArctic collaborator Novartis terminates agreement
BioArctic will keep the full USD 30 million upfront payment despite the collaboration's termination.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioArctic (BIOA B) received notice that Novartis Pharma has decided to terminate their agreement exploring a potential combination treatment. The Option, Collaboration and License Agreement, entered into in August 2025, paired BioArctic's BrainTransporter technology with an undisclosed Novartis antibody. BioArctic said the termination follows Novartis's decision to discontinue the program and is unrelated to BrainTransporter.
BioArctic will retain the full USD 30 million upfront payment and recognize its remaining unrecognized portion as revenue in 2026. The company has entered into five collaboration agreements using BrainTransporter to date.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.BioArctic will retain the full USD 30 million upfront payment. 11% of market cap
- Minor point. Forward-looking: it has not happened yet and may not happen.Remaining unrecognized upfront payment will be recognized as revenue in 2026.
Negative
- Moderate pointNovartis has decided to terminate the August 2025 agreement following its decision to discontinue the program.
Key Figures
- Upfront payment retained
- USD 30 million
- BioArctic will retain the full payment following termination
Key Terms
transferrin receptor medical
blood-brain barrier medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The termination is the result of a Novartis decision to discontinue the program, unrelated to BioArctic's BrainTransporter technology.
BioArctic will retain the full
BioArctic's BrainTransporter technology facilitates the passage of drugs into the brain using the transferrin receptor (TfR). It can be used in a multitude of different therapy areas for delivery of biologics and other modalities to the brain. To date, BioArctic has entered into five collaboration agreements with partners using the BrainTransporter technology.
---
This is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on November 2, 2026, at 9:30 pm CET.
For further information, please contact:
Oskar Bosson, Chief Investor Relations & Communications Officer
E-mail: oskar.bosson@bioarctic.com
Telephone: +46 704 107 180
Jenny Ljunggren, External Communications and Investor Relations Manager
E-mail: jenny.ljunggren@bioarctic.com
Telephone: +46 76 013 86 08
About the BrainTransporter™ technology
BioArctic's BrainTransporter technology is a technology for facilitating the passage of drugs into the brain using the transferrin receptor (TfR). Active transport of medicines across the blood-brain barrier can result in broader brain distribution enabling better efficacy, improved safety profile and dosing convenience. The technology is being applied to several in-house drug projects, as well as external collaborations, and could become part of future collaborations with other pharma companies.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport therapies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/bioarctic/r/bioarctic-collaborator-novartis-terminates-agreement,c4418873
The following files are available for download:
|
​​​​​​​BioArctic collaborator Novartis terminates agreement |
View original content:https://www.prnewswire.com/news-releases/bioarctic-collaborator-novartis-terminates-agreement-302926959.html
SOURCE BioArctic
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.